Indo US Bio-Tech

Indo US Bio-Tech, a microcap company in the agriculture sector, The company has demonstrated positive financial performance in the third quarter of FY24-25, marked by a notable return on capital employed (ROCE) of 36.18%, indicating high management efficiency. Indo US Bio-Tech has shown a strong capacity to manage its debt, reflected in a low Debt to EBITDA ratio of 0.56 times. The company has reported positive results for three consecutive quarters, with net sales for the half-year reaching Rs 45.73 crore, representing a growth of 20.60%. Additionally, the highest quarterly PBDIT was recorded at Rs 5.54 crore, with an operating profit to net sales ratio of 23.51%. Despite these positive indicators, the stock has underperformed the market over the past year, generating a return of -8.77%, compared to the BSE 500's return of 4.53%. The technical trend for the stock remains sideways, showing no clear price momentum, although it has improved from a mildly bearish stance. The majority shareholders of the company are promoters.